Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study
Objective. To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods. The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated wit...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2020/3232950 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556876659687424 |
|---|---|
| author | Chaofeng Li Tao Tang Wenyue Wang |
| author_facet | Chaofeng Li Tao Tang Wenyue Wang |
| author_sort | Chaofeng Li |
| collection | DOAJ |
| description | Objective. To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods. The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded. Results. Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group. Conclusion. The combination use could achieve good efficacy and prolong patients’ PFS time; however, apatinib also reduced the patients’ quality of life and enhanced the nutrition risk and adverse drug reactions. |
| format | Article |
| id | doaj-art-3b7695027bf14e26a9f1cb61034551be |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-3b7695027bf14e26a9f1cb61034551be2025-02-03T05:44:14ZengWileyGastroenterology Research and Practice1687-61211687-630X2020-01-01202010.1155/2020/32329503232950Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized StudyChaofeng Li0Tao Tang1Wenyue Wang2Department of General Surgery, China-Japan Friendship Hospital, Beijing 100029, ChinaDepartment of General Surgery, China-Japan Friendship Hospital, Beijing 100029, ChinaDepartment of General Surgery, China-Japan Friendship Hospital, Beijing 100029, ChinaObjective. To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC). Methods. The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded. Results. Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group. Conclusion. The combination use could achieve good efficacy and prolong patients’ PFS time; however, apatinib also reduced the patients’ quality of life and enhanced the nutrition risk and adverse drug reactions.http://dx.doi.org/10.1155/2020/3232950 |
| spellingShingle | Chaofeng Li Tao Tang Wenyue Wang Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study Gastroenterology Research and Practice |
| title | Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study |
| title_full | Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study |
| title_fullStr | Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study |
| title_full_unstemmed | Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study |
| title_short | Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study |
| title_sort | combination use of tegafur and apatinib as first line therapy in treatment of advanced gastric cancer a single blinded randomized study |
| url | http://dx.doi.org/10.1155/2020/3232950 |
| work_keys_str_mv | AT chaofengli combinationuseoftegafurandapatinibasfirstlinetherapyintreatmentofadvancedgastriccancerasingleblindedrandomizedstudy AT taotang combinationuseoftegafurandapatinibasfirstlinetherapyintreatmentofadvancedgastriccancerasingleblindedrandomizedstudy AT wenyuewang combinationuseoftegafurandapatinibasfirstlinetherapyintreatmentofadvancedgastriccancerasingleblindedrandomizedstudy |